{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:43:25Z","timestamp":1773233005392,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T00:00:00Z","timestamp":1479254400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s10072-016-2771-y","type":"journal-article","created":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T07:59:19Z","timestamp":1479369559000},"page":"319-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Not all drug-induced parkinsonism are the same: the effect of drug class on motor phenotype"],"prefix":"10.1007","volume":"38","author":[{"given":"Renato P.","family":"Munhoz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delcio","family":"Bertucci Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9lio A. G.","family":"Teive","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,16]]},"reference":[{"key":"2771_CR1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clineuro.2010.03.003","volume":"112","author":"RP Munhoz","year":"2010","unstructured":"Munhoz RP, Werneck LC, Teive HA (2010) The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10\u00a0years comparison in tertiary movement disorders clinics. Clin Neurol Neurosurg 112:431\u2013435","journal-title":"Clin Neurol Neurosurg"},{"issue":"Suppl 1","key":"2771_CR2","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/S1353-8020(13)70027-0","volume":"20","author":"PR Burkhard","year":"2014","unstructured":"Burkhard PR (2014) Acute and subacute drug-induced movement disorders. Parkinsonism Relat Disord 20(Suppl 1):S108\u2013S112","journal-title":"Parkinsonism Relat Disord"},{"key":"2771_CR3","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1212\/WNL.52.6.1214","volume":"52","author":"JH Bower","year":"1999","unstructured":"Bower JH, Maraganore DM, McDonnell SK et al (1999) Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976\u20131990. Neurology 52:1214\u20131220","journal-title":"Neurology"},{"key":"2771_CR4","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/mds.26209","volume":"30","author":"R Erro","year":"2015","unstructured":"Erro R, Bhatia KP, Tinazzi M (2015) Parkinsonism following neuroleptic exposure: a double-hit hypothesis? Mov Disord 30:780\u2013785","journal-title":"Mov Disord"},{"key":"2771_CR5","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1136\/jnnp.51.6.850","volume":"51","author":"RJ Hardie","year":"1988","unstructured":"Hardie RJ, Lees AJ (1988) Neuroleptic-induced Parkinson\u2019s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 51:850\u2013854","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2771_CR6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3233\/JPD-140414","volume":"4","author":"R Miguel","year":"2014","unstructured":"Miguel R, Correia AS, Bugalho P (2014) Iatrogenic parkinsonism: the role of flunarizine and cinnarizine. J Parkinsons Dis 4:645\u2013649","journal-title":"J Parkinsons Dis"},{"key":"2771_CR7","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","volume":"157","author":"S Kapur","year":"2000","unstructured":"Kapur S, Zipursky R, Jones C et al (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514\u2013520","journal-title":"Am J Psychiatry"},{"key":"2771_CR8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00002826-200205000-00005","volume":"25","author":"SA Factor","year":"2002","unstructured":"Factor SA (2002) Pharmacology of atypical antipsychotics. Clin Neuropharmacol 25:153\u2013157","journal-title":"Clin Neuropharmacol"},{"key":"2771_CR9","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/0269881105053284","volume":"19","author":"OP Dall\u2019Igna","year":"2005","unstructured":"Dall\u2019Igna OP, Tort AB, Souza DO et al (2005) Cinnarizine has an atypical antipsychotic profile in animal models of psychosis. J Psychopharmacol 19:342\u2013346","journal-title":"J Psychopharmacol"},{"key":"2771_CR10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0028-3908(98)00233-0","volume":"38","author":"O Terland","year":"1999","unstructured":"Terland O, Flatmark T (1999) Drug-induced parkinsonism: cinnarizine and flunarizine are potent uncouplers of the vacuolar H+-ATPase in catecholamine storage vesicles. Neuropharmacology 38:879\u2013882","journal-title":"Neuropharmacology"},{"key":"2771_CR11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427\u2013442","journal-title":"Neurology"},{"key":"2771_CR12","first-page":"153","volume-title":"Recent developments in Parkinsons disease","author":"S Fahn","year":"1987","unstructured":"Fahn S, Elton RL, UPDRS program members (1987) Unified Parkinsons Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB (eds) Recent developments in Parkinsons disease, vol 2. Macmillan Healthcare Information, Florham Park, pp 153\u2013163"},{"key":"2771_CR13","unstructured":"Fahn S, Tolosa E, Concepcion M (1993) Clinical rating scale for tremor. In: Jankovic J, Tolosa E (eds) Parkinson\u2019s disease and movement disorders, 2nd edn. Williams and Wilkins, Baltimore, pp 271\u2013280"},{"key":"2771_CR14","unstructured":"Rush JA Jr. (2000) Handbook of psychiatric measures. American Psychiatric Association, pp 166\u2013168"},{"key":"2771_CR15","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(95)92404-3","volume":"346","author":"AM Lozano","year":"1995","unstructured":"Lozano AM, Lang AE, Galvez-Jimenez N et al (1995) Effect of GPi pallidotomy on motor function in Parkinson\u2019s disease. Lancet 346:1383\u20131387","journal-title":"Lancet"},{"key":"2771_CR16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/mds.870040205","volume":"4","author":"FE Micheli","year":"1989","unstructured":"Micheli FE, Pardal MM, Giannaula R et al (1989) Movement disorders and depression due to flunarizine and cinnarizine. Mov Disord 4:139\u2013146","journal-title":"Mov Disord"},{"key":"2771_CR17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/mds.870130313","volume":"13","author":"JF Mart\u00ed-Mass\u00f3","year":"1998","unstructured":"Mart\u00ed-Mass\u00f3 JF, Poza JJ (1998) Cinnarizine-induced parkinsonism: ten years later. Mov Disord 13:453\u2013456","journal-title":"Mov Disord"},{"key":"2771_CR18","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/bmj.297.6650.722","volume":"297","author":"D Capell\u00e0","year":"1988","unstructured":"Capell\u00e0 D, Laporte JR, Castel JM et al (1988) Parkinsonism, tremor, and depression induced by cinnarizine and flunarizine. BMJ 297:722\u2013723","journal-title":"BMJ"},{"key":"2771_CR19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/mds.870120119","volume":"12","author":"A Negrotti","year":"1997","unstructured":"Negrotti A, Calzetti S (1997) A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism. Mov Disord 12:107\u2013110","journal-title":"Mov Disord"},{"key":"2771_CR20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1517\/14740338.2013.787065","volume":"12","author":"J Lopez-Sendon","year":"2013","unstructured":"Lopez-Sendon J, Mena MA, de Yebenes JG (2013) Drug-induced parkinsonism. Expert Opin Drug Saf 12:487\u2013496","journal-title":"Expert Opin Drug Saf"},{"key":"2771_CR21","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/mds.23828","volume":"26","author":"E Bondon-Guitton","year":"2011","unstructured":"Bondon-Guitton E, Perez-Lloret S, Bagheri H et al (2011) Drug-induced parkinsonism: a review of 17\u00a0years\u2019 experience in a regional pharmacovigilance center in France. Mov Disord 26:2226\u20132231","journal-title":"Mov Disord"},{"key":"2771_CR22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/11598540-000000000-00000","volume":"29","author":"JL L\u00f3pez-Send\u00f3n","year":"2012","unstructured":"L\u00f3pez-Send\u00f3n JL, Mena MA, de Y\u00e9benes JG (2012) Drug-induced parkinsonism in the elderly: incidence, management and prevention. Drugs Aging 29:105\u2013118","journal-title":"Drugs Aging"},{"key":"2771_CR23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2515\/therapie:2005061","volume":"60","author":"JF Mart\u00ed Mass\u00f3","year":"2005","unstructured":"Mart\u00ed Mass\u00f3 JF, Mart\u00ed I, Carrera N et al (2005) Trimetazidine induces parkinsonism, gait disorders and tremor. Therapie 60:419\u2013422","journal-title":"Therapie"},{"key":"2771_CR24","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1590\/S0004-282X2004000500008","volume":"62","author":"G Fabiani","year":"2004","unstructured":"Fabiani G, Pastro PC, Froehner C (2004) Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine. Arq Neuropsiquiatr 62:784\u2013788","journal-title":"Arq Neuropsiquiatr"},{"key":"2771_CR25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00023210-200216010-00003","volume":"16","author":"D Tarsy","year":"2002","unstructured":"Tarsy D, Baldessarini RJ, Tarazi FI (2002) Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16:23\u201345","journal-title":"CNS Drugs"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-016-2771-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-016-2771-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-016-2771-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T10:20:39Z","timestamp":1601202039000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-016-2771-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,16]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["2771"],"URL":"https:\/\/doi.org\/10.1007\/s10072-016-2771-y","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,16]]}}}